Hospital Universitario Central de Asturias -ko ikertzaileekin lankidetzan egindako argitalpenak (40)

2023

  1. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

    Blood Advances

  2. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

2021

  1. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

2020

  1. Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder

    Leukemia and Lymphoma

  2. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

  3. Reply to Brown et al: ‘Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis’

    Leukemia and Lymphoma

2018

  1. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia

    Leukemia and Lymphoma, Vol. 59, Núm. 10, pp. 2318-2326

2017

  1. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia

    Medicina Clinica, Vol. 148, Núm. 8, pp. 381.e1-381.e9

2016

  1. A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia

    Hematological Oncology, Vol. 34, Núm. 2, pp. 84-92

  2. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations

    Oncotarget, Vol. 7, Núm. 49, pp. 80916-80924

  3. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

  4. UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation

    Bone Marrow Transplantation, Vol. 51, Núm. 1, pp. 79-82

2015

  1. A low frequency of losses in 11q chromosome is associated with better outcome and lower rate of genomic mutations in patients with chronic lymphocytic leukemia

    PLoS ONE, Vol. 10, Núm. 12

  2. Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT

    Bone Marrow Transplantation

  3. Non-coding recurrent mutations in chronic lymphocytic leukaemia

    Nature, Vol. 526, Núm. 7574, pp. 519-524

  4. Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy

    Leukemia and Lymphoma, Vol. 56, Núm. 11, pp. 3096-3102

  5. The genotype of the donor for the (GT)n polymorphism in the promoter/enhancer of FOXP3 Is associated with the development of severe acute GVHD but does not affect the GVL effect after myeloablative HLA-Identical allogeneic stem cell transplantation

    PLoS ONE, Vol. 10, Núm. 10

2014

  1. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption

    Haematologica

  2. Hairy cell leukemia treated initially with purine analogs: A retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)

    Leukemia and Lymphoma, Vol. 55, Núm. 5, pp. 1007-1012

  3. Lymphomatoid granulomatosis of central nervous system and lung driven by Epstein Barr virus proliferation: Successful treatment with rituximab-containing chemotherapy

    Mediterranean Journal of Hematology and Infectious Diseases, Vol. 6, Núm. 1